United Therapeutics (NASDAQ:UTHR) CEO Sells $276,054.84 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 516 shares of United Therapeutics stock in a transaction on Monday, March 16th. The stock was sold at an average price of $534.99, for a total transaction of $276,054.84. Following the sale, the chief executive officer directly owned 8,414 shares in the company, valued at $4,501,405.86. This trade represents a 5.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

United Therapeutics Trading Down 0.7%

UTHR stock traded down $3.86 during trading on Monday, reaching $532.26. The stock had a trading volume of 46,357 shares, compared to its average volume of 426,112. The firm has a fifty day moving average price of $486.67 and a 200 day moving average price of $462.28. The company has a market capitalization of $23.33 billion, a P/E ratio of 19.08, a PEG ratio of 1.93 and a beta of 0.84. United Therapeutics Corporation has a 1-year low of $266.98 and a 1-year high of $548.12.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating the consensus estimate of $6.78 by $0.92. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The company had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. During the same period last year, the firm earned $6.19 earnings per share. The company’s revenue was up 7.4% on a year-over-year basis. Sell-side analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Cantor Fitzgerald upped their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday. Wells Fargo & Company lifted their price target on shares of United Therapeutics from $423.00 to $466.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 26th. TD Cowen upped their price target on shares of United Therapeutics from $525.00 to $575.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Royal Bank Of Canada increased their price objective on shares of United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a research note on Thursday, February 26th. Finally, HC Wainwright boosted their target price on shares of United Therapeutics from $525.00 to $600.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. Nine investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $548.09.

Hedge Funds Weigh In On United Therapeutics

Large investors have recently added to or reduced their stakes in the company. Geneos Wealth Management Inc. raised its holdings in shares of United Therapeutics by 141.7% during the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares during the period. AE Wealth Management LLC grew its position in shares of United Therapeutics by 7.6% during the 2nd quarter. AE Wealth Management LLC now owns 864 shares of the biotechnology company’s stock valued at $248,000 after buying an additional 61 shares during the last quarter. Allworth Financial LP lifted its holdings in United Therapeutics by 147.2% in the second quarter. Allworth Financial LP now owns 356 shares of the biotechnology company’s stock worth $102,000 after acquiring an additional 212 shares during the last quarter. Police & Firemen s Retirement System of New Jersey boosted its stake in United Therapeutics by 6.4% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 16,833 shares of the biotechnology company’s stock valued at $4,837,000 after acquiring an additional 1,006 shares during the period. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in United Therapeutics by 8.6% in the second quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 11,589 shares of the biotechnology company’s stock valued at $3,330,000 after acquiring an additional 917 shares during the period. 94.08% of the stock is currently owned by institutional investors.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.